Company

HistoSonics

Medical device company developing noninvasive sonic beam therapy to destroy liver tumors without surgery

Healthcare & Biotech

People

Mike Bluefounder

Funding History

Mar 11, 2026

HistoSonics raised $250M in equity, coinciding with completion of kidney tumor trial enrollment, commencement of pancreatic tumor trial enrollment, and a strategic decision to take private investment instead of proceeding with a planned IPO.

250M

News

Interviews (1)

Mike Blue on HistoSonics' Non-Invasive Tumor Destruction Technology
11 Mar 2026